Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intranasal modified temozolomide
- Development stage
- Preclinical
- Modality
- Gold Nanoparticles → Inorganic Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
Intranasal Modified Temozolomide refers to novel formulations of the alkylating agent temozolomide (TMZ) designed for direct nose-to-brain delivery using nanotechnology. These include derivatives such as temozolomide hexadecyl ester (TMZ16e) and conjugates like anti-ephrin type-A receptor 3 (EphA3)-modified nanoparticles or gold nanoparticles. The modifications aim to enhance brain targeting, bypass the blood–brain barrier, reduce systemic toxicity, and overcome drug resistance in glioblastoma multiforme (GBM). Intranasal administration of these nanoformulations has demonstrated improved cellular uptake in glioma cells, downregulation of O6-methylguanine-DNA methyltransferase (MGMT), reversal of TMZ resistance, increased apoptosis in tumor cells, and significantly prolonged survival in animal models compared to standard TMZ[1][2][4].
- Other names
- intranasal modified temozolomidetemozolomide hexadecyl ester intranasal formulationanti-EphA3-TMZ16e-NPsanti-EphA-3-TMZ16e-NPsanti-EphA 3-TMZ16e-NPsanti-EphA3-TMZ@GNPs
02
Targets
DNAAGT (O6-methylguanine-DNA methyltransferase)
Beyond the preview
Go deeper on intranasal modified temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intranasal modified temozolomide.